[Role and regulation of dopamine D1 receptors in the striatum: implications for the genesis of dyskinesia in Parkinson's disease].

Abstract

L-dopa treatment of Parkinson's disease is complicated in the long term by the appearance of dyskinesia. Hypersensitivity of D1 dopamine receptor has been suggested to play a role in these delayed adverse effects. Hypersensitivity of dopamine D1 receptor in Parkinson's disease can be accounted for by increased levels of Galphaolf, the stimulatory G protein which couples D1 receptor to adenylyl cyclase in the striatum. We here discuss the possible role of D1 receptor signal transduction in the genesis of L-dopa-induced dyskinesia in the light of Galphaolf regulation.

• Authors: J-C Corvol, J-A Girault, D Hervé
• Journal: Revue neurologique (Rev Neurol (Paris)) Vol. 162 Issue 6-7 Pg. 691-702 (Jun 2006) ISSN: 0035-3787 [Print] France
• Vernacular Title: Rôle et régulation du récepteur D1 de la dopamine dans le striatum: implications dans les dyskinésies de la maladie de Parkinson.
• PMID: 16840977 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Antiparkinson Agents
• Receptors, Dopamine D1
• Receptors, Dopamine D2
• Levodopa
• Cyclic AMP
• GTP-Binding Proteins

Topics

• Antiparkinson Agents (adverse effects, therapeutic use)
• Corpus Striatum (metabolism)
• Cyclic AMP (metabolism)
• Dyskinesia, Drug-Induced (complications, etiology, physiopathology)
• GTP-Binding Proteins (drug effects)
• Humans
• Levodopa (adverse effects, therapeutic use)
• Parkinson Disease (complications, drug therapy, physiopathology)
• Receptors, Dopamine D1 (drug effects, metabolism, physiology)
• Receptors, Dopamine D2 (drug effects, physiology)